And then there was one. The sale this year by Akzo Nobel of its Organon Biosciences medicines division has left only Bayer of Germany as a significant European conglomerate that still embraces both chemicals and pharmaceuticals.
Organon’s purchase by Schering Plough of the US highlighted how mid-size pharmaceutical companies – like their larger rivals – have a strong appetite for acquisitions to help boost their pipelines of experimental medicines.
